move to main move to category
  1. HOME
  2. News Release

News Release


Jul 28
Partial Determination of Details of Issuance of Stock Acquisition Rights(Paid-In Capital Stock Options)
(24.5 KB)
Jul 28
Quark Pharmaceuticals Reports Positive Results from a Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury (AKI) in Subjects at High Risk of AKI Following Cardiac Surgery
(58.9 KB)
Jul 27
Issuance of Stock Acquisition Rights (Paid-In Capital Stock Options and Qualified Stock Options)
(152.8 KB)
Jul 19
First Quarterly Results Announcement for the Three Months Ended June 30, 2017 of SBI SECURITIES
(48.7 KB)
Jul 18
Notice Regarding an Investment into FinLeap GmbH
(79.5 KB)
Jun 30
Notice of Launch of First Money Transfer Services between Japan and Kingdom of Thailand by Utilizing Distributed Ledger Technology
(80.6 KB)
Jun 23
FDA has Approved Intraoperative Imaging Agent for Malignant Glioma, One of Brain Tumors, Developed by photonamic
(120.6 KB)
Jun 8
Listing of Sihanoukville Autonomous Port in Cambodia with SBI Royal Securities Serving as Its Lead Manager
(151.8 KB)
May 24
Notice of Memorandum of Understanding on Establishing of a Joint Venture Leasing Company with ReNet Japan Group Co., Cambodia
(130.1 KB)
May 24
Notice Regarding an Investment into R3 HOLDCO LLC, a U.S. FinTech Company
(93 KB)
Apr 28
Notice regarding Adjustment of Conversion Price for \30,000,000,000 Zero Coupon Convertible Bonds Due 2017
(24 KB)
Apr 24
Positive Data of Phase III Clinical Trial in Patients of Non-Muscle Invasive Bladder Cancer were Presented at the 105th Annual Meeting of the Japanese Urological Association
(125.1 KB)
Apr 18
Annual Results Announcement for the Fiscal Year Ended March 31, 2017 of SBI SECURITIES
(40.6 KB)
Mar 31
Notice Regarding the Reorganization of Subsidiaries that Aggregate the Group’s FinTech-related Businesses and the Change of Subsidiary’s Corporate Name
(83.3 KB)
Mar 24
Operational Launch of Insurance Holding Company and Changes to Representatives of Subsidiaries
(98.7 KB)
Mar 15
Notice Regarding an Investment into solarisBank AG
(81.2 KB)
Mar 14
Revision of Dividend Forecast for the Fiscal Year Ending March 31, 2017
(80.7 KB)
Mar 13
SBI Pharma and Chugai Enter an Agreement of Exclusive Marketing Rights for “ALAGLIO® Granule 1.5g” in Japan
(51.1 KB)
Mar 9
Notice Regarding an Investment into Veem Inc.
(83.2 KB)
Mar 7
Notice Regarding an Investment into Wirex Limited through a Fund
(79.6 KB)
Mar 3
Notice Regarding an Investment into Episode Six Limited
(85.3 KB)
Mar 2
Announcing the Successful Completion of RC Cloud Pilot By Japan Bank Consortium -- Moving into the Commercial Phase
(111.3 KB)
Feb 7
Change in Major Shareholder
(101.7 KB)
Jan 27
Notice on the Start of Phase II Clinical Trial using 5-ALA by University of Oxford and SBI Pharmaceuticals
(160.1 KB)
Jan 23
Notice Regarding the Execution of Capital and Business Alliance Agreement between Daiwa Securities Group and the SBI Group on Defined Contribution Pension Plan Business
(126.7 KB)
Jan 19
Third Quarterly Results Announcement for the Nine Months Ended December 31, 2016 of SBI SECURITIES
(66.7 KB)
Get Acrobat Reader
Adobe Reader
You need to download Adobe Reader to view these PDF files.
  • There is no charge for downloading Adobe Reader.
  • The logos of Adobe Reader and Adobe Reader are the registered trademarks of Adobe Systems.